Loading data...
Loading data...
Compares AstraZeneca and Eli Lilly across growth, profitability, cash generation, valuation and balance-sheet signals.
Official head-to-head comparisons for widely followed pairs.
Two pharma momentum stories: AstraZeneca’s oncology depth against Eli Lilly’s obesity-driven surge.
A diversified pipeline or the momentum of a single mega-product — two routes to growth in pharma. AstraZeneca’s depth in oncology spreads its risk across many shots on goal, while Eli Lilly rides an extraordinary obesity-driven surge that concentrates both the upside and the expectations.
AZN.LSE and LLY are compared inside each metric family.
Latest published or live-generated results from the official Datafin analysis.
| # | Stock | Winner | Sales Growth | Return on Equity(ROE) | Return on Invested Capital(ROIC) | Free Cash Flow | Price to Earnings(P/E) | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 🇬🇧 | AZN.LSE AstraZeneca PLC | - | 9.71% | 23.66% | 16.06% | $8.8B | 2,192.58 | 1,117.87 |
| 2 | 🇺🇸 | LLY.US Eli Lilly and Company | 47.44% | 107.64% | 36.95% | $13.6B | 46.83 | 26.42 |